<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ital J Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ital J Pediatr</journal-id>
      <journal-title-group>
        <journal-title>Italian Journal of Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1824-7288</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25326164</article-id>
      <article-id pub-id-type="pmc">4421998</article-id>
      <article-id pub-id-type="publisher-id">68</article-id>
      <article-id pub-id-type="doi">10.1186/s13052-014-0068-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome (IPEX) with intractable diarrhea</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Zama</surname>
            <given-names>Daniele</given-names>
          </name>
          <address>
            <email>daniele.zama@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cocchi</surname>
            <given-names>Ilaria</given-names>
          </name>
          <address>
            <email>ilaria.cocchi2@studio.unibo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Masetti</surname>
            <given-names>Riccardo</given-names>
          </name>
          <address>
            <email>riccardo.masetti@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Specchia</surname>
            <given-names>Fernando</given-names>
          </name>
          <address>
            <email>fernando.specchia@unibo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alvisi</surname>
            <given-names>Patrizia</given-names>
          </name>
          <address>
            <email>patrizia.alvisi@virgilio.it</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gambineri</surname>
            <given-names>Eleonora</given-names>
          </name>
          <address>
            <email>eleonora.gambineri@unifi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Mario</given-names>
          </name>
          <address>
            <email>mario.lima@unibo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pession</surname>
            <given-names>Andrea</given-names>
          </name>
          <address>
            <email>andrea.pession@unibo.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Pediatric Oncology and Haematology Unit &#x201C;Lalla Ser&#xE0;gnoli&#x201D;, Department of Pediatrics, University of Bologna Sant&#x2019;Orsola-Malpighi Hospital, Via Massarenti, 11, Bologna, 40138 Italy </aff>
        <aff id="Aff2"><label/>Pediatric Department, Maggiore Hospital, Bologna, Italy </aff>
        <aff id="Aff3"><label/>Department of &#x2018;NEUROFARBA&#x2019;, Section of Child&#x2019;s Health, University of Florence, Florence, Italy </aff>
        <aff id="Aff4"><label/>BMT Unit, Department of Hematology-Oncology, Anna Meyer Children&#x2019;s Hospital, Florence, Italy </aff>
        <aff id="Aff5"><label/>Department of Pediatric Surgery, University of Bologna, Bologna, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <elocation-id>68</elocation-id>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Zama et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>The syndrome of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) is a rare disorder caused by mutations in the FOXP3 gene. Diarrhea, diabetes and dermatitis are the hallmark of the disease, with a typical onset within the first months of life. We describe the case of a twelve-year old male affected by a very late-onset IPEX with intractable enteropathy, which markedly improved after starting Sirolimus as second-line treatment. This case suggests that IPEX should always be considered in the differential diagnosis of watery intractable diarrhea, despite its unusual onset.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)</kwd>
        <kwd>Sirolimus</kwd>
        <kwd>Forkhead box P3 (FOXP3)</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Correspondence</title>
      <p>The syndrome of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is a rare disorder, characterized by diarrhea, type-1 diabetes mellitus (T1DM) and dermatitis with onset within the first months of life [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. Diarrhea is intractable and persists despite dietary exclusions and bowel rest, resulting in malabsorption and failure to thrive [<xref ref-type="bibr" rid="CR3">3</xref>]; T1DM can precede or follow enteritis [<xref ref-type="bibr" rid="CR4">4</xref>-<xref ref-type="bibr" rid="CR6">6</xref>]; dermatitis is severe with eczematiform, ichthyosiform or psoriasiform aspects [<xref ref-type="bibr" rid="CR7">7</xref>-<xref ref-type="bibr" rid="CR10">10</xref>], other autoimmune diseases are often associated [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>IPEX is caused by germ-line mutations in the FOXP3 gene, a key regulator of immune tolerance, located in the X-chromosome at Xp11.23-Xq13.3 [<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR17">17</xref>]. It is critical for the function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cells (T<sub>REG</sub>) and for the maintenance of peripheral immunologic tolerance [<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <sec id="Sec2">
        <title>Findings</title>
        <p>We describe a 12-year-old boy born at term from natural birth after an uncomplicated pregnancy from unrelated parents, referred to our hospital for severe enteritis started one month before with liquid mucus-haematic diarrhoea (height: 50<sup>th</sup> centile, weight: 10<sup>th</sup> centile, regularly vaccinated). No potentially triggering events have been reported, such as vaccinations, viral infections or changes in nutrition. In his past history he had recurring episodes of mild atopic dermatitis since the first year of life, a high level of total IgE (400 UI/L), and a constipated bowel (once every two/three days).</p>
        <p>On admission, he was dehydrated (7% of weight loss). Blood tests revealed hypoproteinaemia and hypogammaglobulinemia (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>), so albumin was replaced.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>The molecular and clinical features of the patient with IPEX who received sirolimus have been reported</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th colspan="2">
<bold>Patient</bold>
</th><th colspan="4">
<bold>Mutation</bold>
</th><th rowspan="2">
<bold>Clinical features</bold>
</th><th rowspan="2">
<bold>Histology</bold>
</th><th colspan="3">
<bold>Management</bold>
</th><th rowspan="2">
<bold>Outcome</bold>
</th><th rowspan="2">
<bold>Ref.</bold>
</th></tr><tr valign="top"><th/><th>
<bold>Age at onset age at dg</bold>
</th><th>
<bold>Nucleotide change</bold>
</th><th>
<bold>AA change</bold>
</th><th valign="top">
<bold>FOXP3</bold>
</th><th>
<bold>Molecular defect</bold>
</th><th>
<bold>Previous therapy</bold>
</th><th>
<bold>SIR</bold>
</th><th>
<bold>HSCT</bold>
</th></tr></thead><tbody><tr valign="top"><td valign="middle">1</td><td valign="middle">7 y 10 y</td><td valign="middle">c.968-20A&gt;C</td><td valign="middle">NA</td><td valign="middle">NA</td><td valign="middle">NA</td><td valign="middle">Dermatitis, enteropathy</td><td valign="middle">Lymphoplasmocellular eosinophilic infiltrate. Villous atrophy.</td><td valign="middle">Steroids, AZA, CsA, FK, MTX. TPN, Total colectomy at 10 y</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 16 yr on SIR+MTX.</td><td valign="middle">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle">2<sup>*</sup>
</td><td valign="middle">2 m NA</td><td valign="middle" colspan="4">NA</td><td valign="middle">Enteropathy, erythematous eczema-like dermatitis</td><td valign="middle">Lymphoplasmocellular infiltrate with marked eosinophilia. High rate of enterocyte apoptosis. Subtotal villous atrophy.</td><td valign="middle">Steroids, FK, AZA</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable for 1.5 yr on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle">3<sup>*</sup>
</td><td valign="middle">2 m NA</td><td valign="middle" colspan="4">NA</td><td valign="middle">Enteropathy, erythematous eczema-like dermatitis</td><td valign="middle">Similar findings with that of his brother (pt.4)</td><td valign="middle">Steroids, FK; AZA</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable for 6 m on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr valign="top"><td valign="middle">4</td><td valign="middle">2 y 4 y</td><td valign="middle">1061 delC</td><td valign="middle">Frameshift P354Q</td><td valign="middle">NA</td><td valign="middle">Premature stop codon. Truncated FKH domain</td><td valign="middle">Enteropathy, nonspecific dermatitis</td><td valign="middle">Mild villous blunting</td><td valign="middle">Metronidazole, steroids, mesalamine, IFX, AZA, 6-MP</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 7 yr</td><td valign="middle">[<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr valign="top"><td valign="middle">5</td><td valign="middle">1 w 7 y</td><td valign="middle">200G&gt;T</td><td valign="middle">Q70H</td><td valign="middle">NA</td><td valign="middle">Predicted abnormal reading frame</td><td valign="middle">Eczema, enteropathy, AHA, ITP, arthritis</td><td valign="middle">Inflammation with villous atrophy</td><td valign="middle">IVIG, steroids, TPN, antibiotics</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 8 yr</td><td valign="middle">[<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr valign="top"><td valign="middle">6<sup>*</sup>
</td><td valign="middle">3 w NA</td><td valign="middle">g.-6247-4859del</td><td valign="middle">NA</td><td valign="middle">&#x2193;</td><td valign="middle">Accumulation of unspliced mRNA</td><td valign="middle">Skin/food allergies, Enteropathy, erythematous- eczematous skin rash</td><td valign="middle">Lymphoplasmocellular infiltrate with marked eosinophilia. High rate of enterocytes apoptosis. Severe to total villous atrophy</td><td valign="middle">Steroids, FK, AZA TPN</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable for 6 yr on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle">7<sup>*</sup>
</td><td valign="middle">2 m NA</td><td valign="middle">g.-6247-4859del</td><td valign="middle">NA</td><td valign="middle">&#x2193;</td><td valign="middle">Accumulation of unspliced mRNA</td><td valign="middle">Skin/food allergies, Eczema, Enteropathy</td><td valign="middle">NA</td><td valign="middle">Steroids, FK, AZA TPN</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable for 4 yr on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr valign="top"><td valign="middle">8</td><td valign="middle">5 w NA</td><td valign="middle">g.-6247-4859del</td><td valign="middle">NA</td><td valign="middle">&#x2193;</td><td valign="middle">Accumulation of unspliced mRNA</td><td valign="middle">Enteropathy, Eczema, Allergy</td><td valign="middle">NA</td><td valign="middle">Steroids, FK, AZA</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 9 yr on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle">9</td><td valign="middle">3 w NA</td><td valign="middle">g.-6247-4859del</td><td valign="middle">NA</td><td valign="middle">&#x2193;</td><td valign="middle">Accumulation of unspliced mRNA</td><td valign="middle">Enteropathy, Eczema, HP gastritis, Allergy</td><td valign="middle">NA</td><td valign="middle">Steroids, FK AZA</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 6 yr on SIR+AZA</td><td valign="middle">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle">10</td><td valign="middle">Birth NA</td><td valign="middle">g.-1121 T&gt;G</td><td valign="middle">F374C</td><td valign="middle">&#x2193;</td><td valign="middle">Full length FOXP3 with abnormal FKH domain</td><td valign="middle">T1DM, HTH, Enteropathy, Eczema, AHA, ITP, Allergy.</td><td valign="middle">NA</td><td valign="middle">Steroids, FK506</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Died at 14 m during HSCT induction</td><td valign="middle">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle">11</td><td valign="middle">6 w NA</td><td valign="middle">751-753 del GAG</td><td valign="middle">E251del</td><td valign="middle">&#x2193;</td><td valign="middle">Disrupts FOXP3 oligomerisation</td><td valign="middle">Enteropathy, Eczema, HTH, Interstitial Nephritis, AHA, Allergy.</td><td valign="middle">NA</td><td valign="middle">FK506</td><td valign="middle">Y</td><td valign="middle">Y</td><td valign="middle">Died at 10 yr after HSCT</td><td valign="middle">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr valign="top"><td valign="middle">12</td><td valign="middle">1 m 6 y</td><td valign="middle">1150G&gt;A</td><td valign="middle">A384T</td><td valign="middle">&#x2193;</td><td valign="middle">Full length FOXP3 with abnormal FKH domain</td><td valign="middle">Enteropathy, Eczema, FTT, T1DM, AHA, Interstitial Pneumonia, Alopecia, Thyroiditis.</td><td valign="middle">Eosinophil infiltration without villous atrophy</td><td valign="middle">IVIG, CsA, steroids, TPN, fludarabine-autologous lymphocytes, FK, MTX, Rituximab, cyclophosphamide.</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable at 16 yr on others drugs</td><td valign="middle">[<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr valign="top"><td valign="middle">13</td><td valign="middle">Birth 7 w</td><td valign="middle">1150G&gt;A</td><td valign="middle">A384T</td><td valign="middle">&#x2193;</td><td valign="middle">Full length FOXP3 with abnormal FKH domain</td><td valign="middle">Enteropathy, T1DM, Exfoliative Dermatitis, HTH, Pancytopenia</td><td valign="middle">NA</td><td valign="middle">TPN</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Died at 7 w</td><td valign="middle">[<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr valign="top"><td valign="middle">14</td><td valign="middle">Birth 4&#xBD; y</td><td valign="middle">AAUAAA/AAUAAG</td><td valign="middle">NA</td><td valign="middle">&#x2193;</td><td valign="middle">Polyadenylation defect resulting in unstable FOXP3 mRNA</td><td valign="middle">Enteropathy, Dermatitis, FTT, T1D.</td><td valign="middle">NA</td><td valign="middle">MTX, steroids, TPN.</td><td valign="middle">Y</td><td valign="middle">Y</td><td valign="middle">Stable at 1 yr</td><td valign="middle">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr valign="top"><td valign="middle">15</td><td valign="middle">1 w</td><td valign="middle">1015C&gt;G</td><td valign="middle">P339A</td><td valign="middle">&#x2193;</td><td valign="middle">Missense mutation. Predicted to yield full length FOXP3</td><td valign="middle">Enteropathy, Eczema, T1DM, FTT, Euthyroid Thyroiditis, AIH, AHA</td><td valign="middle">Villous atrophy</td><td valign="middle">Steroids, FK; AZA</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Died at 5.5 m before HSCT</td><td valign="middle">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr valign="top"><td valign="middle">16</td><td valign="middle">3 m 1y</td><td valign="middle">Exon 10</td><td valign="middle">NA</td><td valign="middle">NA</td><td valign="middle">NA</td><td valign="middle">FTT, Enteropathy, Eczematous Dermatitis, ITP stomatitis</td><td valign="middle">NA</td><td valign="middle">Cyclophosphamide, VCR, TPN</td><td valign="middle">Y</td><td valign="middle">N</td><td valign="middle">Stable 2&#xBD; yr on other drugs</td><td valign="middle">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<sup>*</sup>Brothers; 6-MP 6-Mercaptopurina; AHA autoimmune haemolytic anaemia; AIH Autoimmune hepatits; AZA Azathioprine; CsA Cyclosposporine; FTT: failure to thrive; FK: tacrolimus; HSCT hematopoietic stem cell transplantation; HTH Hypothyroidism; IFX Infliximab; ITP immune thrombocytopenic purpura; IVIG Intravenous Immunoglobulin; Y: Yes; yr: years; m: months; MTX Methotrexate; NA Not Available; N: No; Ref. References; SIR Sirolimus; T1DM Type 1 Diabetes mellitus; TPN Total Parenteral Nutrition; VCR Vincristine; w: weeks; &#x2193;: reduction of expression.</p></table-wrap-foot></table-wrap></p>
        <p>Abdominal ultrasound highlighted wall thickening of the bowel loops. Esophagogastroduodenoscopy (EGDS) and colonoscopy revealed ulcerative lesions at the stomach, duodenum, terminal ileum and colon, giving rise to a suspect of inflammatory bowel disease. Biopsies revealed villous blunting and inflammatory infiltration of the mucosa. After starting intravenous methylprednisolone, metronidazole and parenteral nutrition a partial remission was observed.</p>
        <p>Ten days later, for a worsening of symptoms, EGDS and colonoscopy were repeated, with a superimposable picture. Particularly, the biopsies of the colon showed lympho-granulocytic acute inflammation with Graft versus Host Disease-like aspect, a lesion typically reported in IPEX (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR30">30</xref>]. Due to the inability to control the symptoms the patient underwent ileostomy.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Biopsy of the colon mucosa highlights a marked inflammatory infiltrate.</bold> (<bold>A</bold>: H&amp;E 5x) with a GVHD-like aspect characterized by a prevalence of lymphocytes CD8+ (red; <bold>B</bold>) than lymphocytes CD4+ (red; <bold>C</bold>). Rare lymphocytes expressing FOXP3 were found (red; <bold>D</bold>).</p></caption><graphic xlink:href="13052_2014_68_Fig1_HTML" id="MO1"/></fig></p>
        <p>Despite the age of the patient was atypical for the onset of IPEX, we evaluated the presence of autoantibodies to harmonin, which resulted positive (&gt;100 U.A.). Then, diagnosis was confirmed by the genetic examination of FOXP3 gene, revealing a mutation in the exon 9 (1040G&#x2009;&gt;&#x2009;A), with substitution of Arginine to Histidine (R347H). The mother resulted negative. The total number of lymphocyte and lymphocyte subpopulations was normal, particularly T<sub>REG</sub> were 5% of the total number.</p>
        <p>Intravenous cyclosporine (range: 200-350&#xA0;mg/dl) and methylprednisolone (2&#xA0;mg/kg) were started, which reduced diarrhea and abdominal pain. After sixty days of parenteral nutrition the patient returned to oral feeding with the normalization of albumin levels (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Because of the onset of post-prandial hyperglycaemias, we excluded T1DM (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) and glycaemia normalized after tapering steroid therapy. For a new worsening of the disease we introduced sirolimus (0.15&#xA0;mg/kg/day; range: 8-12&#xA0;mg/dl). The patient improved with a progressive reduction of intensity and frequency of abdominal pain and mucus emission. A new colonoscopy highlighted a marked decrease of the inflammation. After thirty-four days since the beginning of sirolimus, cyclosporine was suspended. After twelve months the patient is well, without recurrence of the disease.</p>
      </sec>
      <sec id="Sec3">
        <title>Conclusions</title>
        <p>This case indicates that IPEX can have an atypical age of presentation. Thus, it should always be considered in the differential diagnosis of intractable diarrhea.</p>
        <p>Four patients have been previously reported with IPEX with the same amino-acid substitution (R347H) found in our patient. The age of onset for all these subjects was within the first year of life and the first symptoms were recurrent ear infection, high IgE levels, T1DM, and gastritis. All had gastrointestinal symptoms with failure to thrive: two intractable diarrhea, two severe gastritis with mucosal atrophy or eosinophilic infiltration. Other symptoms were: coombs-negative haemolytic anaemia, food allergy, pancreatic exocrine failure, intractable hypertension, intestinal metaplasia, steatorrhea, and hypogammaglobulinemia. Patients received corticosteroid and calcineurin inhibitors. One patient died after allogeneic hematopoietic stem cell transplantation (HSCT) due to an infection.</p>
        <p>Recently, evidence that patients with a severe form of IPEX may have circulating FOXP3<sup>+</sup> T cells, as it is the case of our patient, which suggests that the cellular basis for the disease may be a result of a functional defect of Treg cells [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR26">26</xref>]. Mainly, R347H mutated-FOXP3 has been demonstrated as effective as wild-type-FOXP3 in converting normal T cell into Treg in vitro [<xref ref-type="bibr" rid="CR31">31</xref>] and in maintaining the ability to suppress the production of cytokines, hallmark of Treg cells, conferring suppressive capacity on CD4<sup>+</sup> T cells.</p>
        <p>In 2005, three patients were successfully treated with sirolimus [<xref ref-type="bibr" rid="CR19">19</xref>]. Since then, 16 patients received sirolimus and nine are in complete or partial remission (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Considering that sirolimus seems to be as effective as the calcineurin inhibitors, with less toxic effects, it can be considered as a valid therapeutic option for bringing these patients to HSCT in their best clinical condition.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Variables of our patient at the time of admission to our hospital, when he started the second line therapy with Sirolimus and after three months since the begging of this therapy</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Variables</bold>
</th><th>
<bold>Reference range, age and sex-adjusted</bold>
</th><th>
<bold>Admission</bold>
</th><th>
<bold>Start SIROLIMUS</bold>
</th><th>
<bold>3 months after SIROLIMUS</bold>
</th></tr></thead><tbody><tr valign="top"><td>
<bold>White-cell count &#x2014; per mm</bold>
<sup><bold>3</bold></sup>
</td><td>4.5 - 13.5</td><td>15.01</td><td>4.04</td><td>5.01</td></tr><tr valign="top"><td>
<bold>Hemoglobin &#x2014; g/dl</bold>
</td><td>11.5 - 14.5</td><td>16.3</td><td>11.7</td><td>11.5</td></tr><tr valign="top"><td>
<bold>Hematocrit &#x2014;%</bold>
</td><td>35 - 42</td><td>46.0</td><td>34.4</td><td>35.7</td></tr><tr valign="top"><td>
<bold>Differential count &#x2014;%</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td>Neutrophils</td><td>40.0 - 74.0</td><td>89.6</td><td>51.2</td><td>48.0</td></tr><tr valign="top"><td>Lymphocytes</td><td>19.0 - 48.0</td><td>6.6</td><td>30.3</td><td>38.0</td></tr><tr valign="top"><td>Monocytes</td><td>3.0 - 9.0</td><td>2.4</td><td>13.5</td><td>7.6</td></tr><tr valign="top"><td>Eosinophils</td><td>0.0 - 6.0</td><td>0.4</td><td>1.7</td><td>4.4</td></tr><tr valign="top"><td>Basophils</td><td>0.0 - 1.5</td><td>0.3</td><td>1.1</td><td>0.7</td></tr><tr valign="top"><td>
<bold>Platelet count &#x2014; per mm</bold>
<sup><bold>3</bold></sup>
</td><td>250 - 550</td><td>522</td><td>247</td><td>273</td></tr><tr valign="top"><td>
<bold>Glucose &#x2014; mg/dl</bold>
</td><td>60 - 100</td><td>125</td><td>107</td><td>77</td></tr><tr valign="top"><td>
<bold>Insulinemia &#x2014; microU/mL</bold>
</td><td>7 - 24</td><td valign="middle" rowspan="4"/><td>6.8</td><td/></tr><tr valign="top"><td>
<bold>C-peptide &#x2014; ng/mL</bold>
</td><td>1.1 - 4.4</td><td>2.7</td><td/></tr><tr valign="top"><td>
<bold>Islet cell autoantibodies</bold>
</td><td>Neg</td><td>Neg</td><td>Neg</td></tr><tr valign="top"><td>
<bold>Glutamic acid decarboxylase&#x2014; UI/ml</bold>
</td><td>&lt;10 Neg</td><td>Neg</td><td>Neg</td></tr><tr valign="top"><td/><td>&gt;10 Pos</td><td/><td/><td/></tr><tr valign="top"><td>
<bold>UREA &#x2014; mg/dl</bold>
</td><td>15 - 50</td><td>72</td><td>40</td><td>18</td></tr><tr valign="top"><td>
<bold>Creatinine &#x2014; mg/dl</bold>
</td><td>0.5 - 1</td><td>0.91</td><td>0.54</td><td>0.35</td></tr><tr valign="top"><td>
<bold>Uric Ac. &#x2014; mg/dl</bold>
</td><td>2.2 - 6.6</td><td>8.6</td><td>5.2</td><td>3.4</td></tr><tr valign="top"><td>
<bold>Total Colesterol &#x2014; mg/dl</bold>
</td><td>130 - 204</td><td rowspan="4"/><td>121</td><td valign="middle" rowspan="4"/></tr><tr valign="top"><td>
<bold>TG &#x2014; mg/dl</bold>
</td><td>31 - 108</td><td>40</td></tr><tr valign="top"><td>
<bold>HDL &#x2014; mg/dl</bold>
</td><td>&gt; 35</td><td>62</td></tr><tr valign="top"><td>
<bold>LDL &#x2014; mg/dl</bold>
</td><td>&lt; 170</td><td>50</td></tr><tr valign="top"><td>
<bold>Electrolytes &#x2014; mmol/L</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td>Sodium</td><td>136 - 146</td><td>128</td><td>139</td><td>142</td></tr><tr valign="top"><td>Potassium</td><td>3.5 - 5.3</td><td>5.5</td><td>4.3</td><td>4.3</td></tr><tr valign="top"><td>Chlorine</td><td>98 - 106</td><td>85</td><td>103</td><td>105</td></tr><tr valign="top"><td>Calcium</td><td>8.8 - 10.8</td><td>9.6</td><td>9.3</td><td>9.2</td></tr><tr valign="top"><td>
<bold>Phosphorus &#x2014; mg/dl</bold>
</td><td>2.9 - 5.4</td><td>7.6</td><td>5</td><td>4.4</td></tr><tr valign="top"><td>
<bold>Magnesium &#x2014; mg/dl</bold>
</td><td>1.6 - 2.6</td><td>2.2</td><td>1.6</td><td>2.1</td></tr><tr valign="top"><td>
<bold>Plasma Osmolarity &#x2014; mOsm/L</bold>
</td><td>278 - 305</td><td>266</td><td/><td/></tr><tr valign="top"><td>
<bold>Protein &#x2014; g/dl</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td>Total</td><td>6,4 - 8.1</td><td>4.1</td><td>6.2</td><td>6.7</td></tr><tr valign="top"><td>Albumin</td><td>3.5 - 5</td><td>2.4</td><td>4.2</td><td>4.3</td></tr><tr valign="top"><td>&#x3B3; &#x2013;Globulin &#x2014;%</td><td>11.1 - 18.8</td><td>10.5</td><td>11.4</td><td>13.4</td></tr><tr valign="top"><td>
<bold>Bilirubin &#x2014; mg/dl</bold>
</td><td/><td/><td/><td/></tr><tr valign="top"><td>Total</td><td>0.20 - 1.10</td><td>1.54</td><td>0.44</td><td>0.3</td></tr><tr valign="top"><td>Direct/Indirect</td><td>0.00-0.30/&lt; 0.80</td><td>0.48/1.06</td><td>0.21/0.23</td><td>0.1/0.2</td></tr><tr valign="top"><td>
<bold>AST/ALT &#x2014; U/L</bold>
</td><td>&lt; 38/&lt; 41</td><td>44/34</td><td>16/10</td><td>22/17</td></tr><tr valign="top"><td>
<bold>Total Amylase &#x2014; U/L</bold>
</td><td>30 - 100</td><td>50</td><td>60</td><td/></tr><tr valign="top"><td>
<bold>Iron &#x2014; &#x3BC;g/dl</bold>
</td><td>53 - 119</td><td valign="middle" rowspan="3"/><td>47</td><td>52</td></tr><tr valign="top"><td>
<bold>U.I.B.C./T.I.B.C. &#x2014; &#x3BC;g/dl</bold>
</td><td>110-330/250-400</td><td>300/347</td><td>273/325</td></tr><tr valign="top"><td>
<bold>Ferritin &#x2014; ng/mL</bold>
</td><td>7 - 140</td><td>22</td><td>16</td></tr><tr valign="top"><td>
<bold>TSH &#x2014; microU/mL</bold>
</td><td>0.6 - 6.3</td><td valign="middle" rowspan="5"/><td>1.93</td><td>1.02</td></tr><tr valign="top"><td>
<bold>FT3 &#x2014; pg/mL</bold>
</td><td>2.5 - 5.5</td><td>3.6</td><td>4.1</td></tr><tr valign="top"><td>
<bold>FT4 &#x2014; pg/mL</bold>
</td><td>9.0 - 17.0</td><td>20.7</td><td>12.9</td></tr><tr valign="top"><td>
<bold>ATA &#x2014; UI/mL</bold>
</td><td>&lt; 115</td><td>23</td><td>16</td></tr><tr valign="top"><td>
<bold>Anti TPO Ab &#x2014; UI/mL</bold>
</td><td>&lt; 34</td><td>12</td><td>13</td></tr><tr valign="top"><td>
<bold>ESR &#x2014; mm</bold>
</td><td>&lt; 15</td><td>6</td><td>15</td><td>9</td></tr><tr valign="top"><td>
<bold>CRP &#x2014; mg/dl</bold>
</td><td>&lt; 0.5</td><td>0.05</td><td>2.05</td><td>0.09</td></tr><tr valign="top"><td rowspan="2">
<bold>Ab anti harmonine IgG &#x2014; U.A.</bold>
</td><td>&lt; 3.0 absent</td><td valign="middle" rowspan="2"/><td valign="middle" rowspan="2">&gt;100</td><td valign="middle" rowspan="2"/></tr><tr valign="top"><td>&gt; 0.3 present</td></tr><tr valign="top"><td>
<bold>ANA</bold>
</td><td>&lt; 1:80</td><td/><td>&lt; 1:80</td><td valign="middle" rowspan="5"/></tr><tr valign="top"><td>
<bold>AMA</bold>
</td><td>&lt; 1:40</td><td/><td>&lt; 1:40</td></tr><tr valign="top"><td>
<bold>ENA</bold>
</td><td>&lt; 0,7 Neg</td><td/><td>Neg</td></tr><tr valign="top"><td/><td>0.7 - 1-0 Bl</td><td/><td/></tr><tr valign="top"><td/><td>&gt; 1.0 Pos</td><td/><td/></tr></tbody></table><table-wrap-foot><p>ALT Alanine aminotransferase, AMA Anti-mitochondrial antibodies, ANA Antinuclear antibodies, anti-TPO Ab Anti-ThyroidPeroxidase Antibodies, AST aspartate aminotransferase, ATA Anti-Thyroglobulin Antibodies, Bl Borderline, CRP C-reactive protein, ENA Extractable Nuclear Antigens, ESR erythrocyte sedimentation rate, FT3 Free Triiodothyronine, FT4 Free Thyroxine, HDL High-Density Lipoprotein, LDL Low-Density Lipoprotein, Neg Negative, Pos Positive, T.I.B.C. Total iron-binding capacity, TG triglycerides, TSH Thyroid-Stimulating Hormone, U.I.B.C. Unsaturated Iron Binding Capacity.</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the parents of the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec id="Sec5">
      <title>Ethical approval</title>
      <p>Internal ethical committee of Sant-Orsola approved the study.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>IPEX</term>
          <def>
            <p>Syndrome of immune dysregulation, polyendocrinopathy, enteropathy, X linked</p>
          </def>
        </def-item>
        <def-item>
          <term>T1DM</term>
          <def>
            <p>Type-1 diabetes mellitus</p>
          </def>
        </def-item>
        <def-item>
          <term>EGDS</term>
          <def>
            <p>Esophagogastroduodenoscopy</p>
          </def>
        </def-item>
        <def-item>
          <term>FKH</term>
          <def>
            <p>Forkhead/winged helix domain</p>
          </def>
        </def-item>
        <def-item>
          <term>mTOR</term>
          <def>
            <p>Mammalian target of rapamycin</p>
          </def>
        </def-item>
        <def-item>
          <term>HSCT</term>
          <def>
            <p>Hematopoietic stem cell transplantation</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>ZD and IC reviewed relevant articles on the literature, collected all the patient&#x2019;s data and drew the manuscript. FS and PA contributed to the diagnosis and provided clinical assistance. RM, ML and AP contributed to the conception and design, and revisited critically the manuscript. EG&#xA0;carried out the molecular genetic studies and drafted the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bacchetta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Passerini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gambineri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Perroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dagna-Bricarelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sartirana</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Matthes-Martin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lawitschka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Azzari</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Levings</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Roncarolo</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Defective regulatory and effector T cell functions in patients with FOXP3 mutations</article-title>
          <source>J Clin Invest</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>1713</fpage>
          <lpage>1722</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI25112</pub-id>
          <pub-id pub-id-type="pmid">16741580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wildin</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Smyk-Pearson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Filipovich</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome</article-title>
          <source>J Med Genet</source>
          <year>2002</year>
          <volume>39</volume>
          <fpage>537</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.39.8.537</pub-id>
          <pub-id pub-id-type="pmid">12161590</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vliet HJJ Van</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nieuwenhuis</surname>
              <given-names>EE</given-names>
            </name>
          </person-group>
          <article-title>IPEX as a Result of Mutations in FOXP3</article-title>
          <source>Clin Dev Immunol</source>
          <year>2007</year>
          <volume>2007</volume>
          <fpage>3</fpage>
          <lpage>8</lpage>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gambineri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Perroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Passerini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bianchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Doglioni</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box protein 3 expression and disease severity</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2008</year>
          <volume>122</volume>
          <fpage>1105</fpage>
          <lpage>1113</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2008.09.027</pub-id>
          <pub-id pub-id-type="pmid">18951619</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peake</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>McCrossin</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Byrne</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea</article-title>
          <source>Arch Dis Child Fetal Neonatal Ed</source>
          <year>1996</year>
          <volume>74</volume>
          <fpage>F195</fpage>
          <lpage>F199</lpage>
          <pub-id pub-id-type="doi">10.1136/fn.74.3.F195</pub-id>
          <pub-id pub-id-type="pmid">8777684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baud</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Canioni</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Le Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Radford</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rieu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dupuis-Girod</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cerf-Bensussan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brousse</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>344</volume>
          <fpage>1758</fpage>
          <lpage>1762</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200106073442304</pub-id>
          <pub-id pub-id-type="pmid">11396442</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruemmele</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Moes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>de Serre</surname>
              <given-names>NP-M</given-names>
            </name>
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Clinical and molecular aspects of autoimmune enteropathy and immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome</article-title>
          <source>Curr Opin Gastroenterol</source>
          <year>2008</year>
          <volume>24</volume>
          <fpage>742</fpage>
          <lpage>748</lpage>
          <pub-id pub-id-type="doi">10.1097/MOG.0b013e32830c9022</pub-id>
          <pub-id pub-id-type="pmid">19122524</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nieves</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Phipps</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome</article-title>
          <source>Arch Dermatol</source>
          <year>2004</year>
          <volume>140</volume>
          <fpage>466</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.140.4.466</pub-id>
          <pub-id pub-id-type="pmid">15096376</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Benedetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Insalaco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Diamanti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cortis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muratori</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lamioni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carsetti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cusano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>De Vito</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Perroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gambarara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bottazzo</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Ugazio</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome</article-title>
          <source>Clin Gastroenterol Hepatol</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>653</fpage>
          <lpage>659</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cgh.2005.12.014</pub-id>
          <pub-id pub-id-type="pmid">16630773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halabi-Tawil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Fraitag</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brousse</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>De Prost</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bodemer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</article-title>
          <source>Br J Dermatol</source>
          <year>2009</year>
          <volume>160</volume>
          <fpage>645</fpage>
          <lpage>651</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08835.x</pub-id>
          <pub-id pub-id-type="pmid">18795917</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torgerson</surname>
              <given-names>TR</given-names>
            </name>
          </person-group>
          <article-title>Regulatory T cells in human autoimmune diseases</article-title>
          <source>Springer Semin Immunopathol</source>
          <year>2006</year>
          <volume>28</volume>
          <fpage>63</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.1007/s00281-006-0041-4</pub-id>
          <pub-id pub-id-type="pmid">16902772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bennett</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Christie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramsdell</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brunkow</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Whitesell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Saulsbury</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Chance</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>20</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1038/83713</pub-id>
          <pub-id pub-id-type="pmid">11137993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wildin</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Ramsdell</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Peake</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Faravelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Buist</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Levy-Lahad</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mazzella</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Perroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bricarelli</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Byrne</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>McEuen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Proll</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Appleby</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brunkow</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>18</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1038/83707</pub-id>
          <pub-id pub-id-type="pmid">11137992</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chatila</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Blaeser</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lederman</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Voulgaropoulos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Helms</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome</article-title>
          <source>J Clin Invest</source>
          <year>2000</year>
          <volume>106</volume>
          <fpage>R75</fpage>
          <lpage>R81</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI11679</pub-id>
          <pub-id pub-id-type="pmid">11120765</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kretschmer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Frampton</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Polansky</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>MacIsaac</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Fraenkel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>von Boehmer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Foxp3 occupancy and regulation of key target genes during T-cell stimulation</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>445</volume>
          <fpage>931</fpage>
          <lpage>935</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05478</pub-id>
          <pub-id pub-id-type="pmid">17237765</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Josefowicz</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Kas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>T-T</given-names>
            </name>
            <name>
              <surname>Gavin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rudensky</surname>
              <given-names>AY</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>445</volume>
          <fpage>936</fpage>
          <lpage>940</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05563</pub-id>
          <pub-id pub-id-type="pmid">17237761</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Borde</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heissmeyer</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Feuerer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lapan</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Stroud</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Benoist</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>FOXP3 controls regulatory T cell function through cooperation with NFAT</article-title>
          <source>Cell</source>
          <year>2006</year>
          <volume>126</volume>
          <fpage>375</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2006.05.042</pub-id>
          <pub-id pub-id-type="pmid">16873067</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bettelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dastrange</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oukka</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>5138</fpage>
          <lpage>5143</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0501675102</pub-id>
          <pub-id pub-id-type="pmid">15790681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bindl</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perroni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome)</article-title>
          <source>J Pediatr</source>
          <year>2005</year>
          <volume>147</volume>
          <fpage>256</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2005.04.017</pub-id>
          <pub-id pub-id-type="pmid">16126062</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yong</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <article-title>Use of sirolimus in IPEX and IPEX-like children</article-title>
          <source>J Clin Immunol</source>
          <year>2008</year>
          <volume>28</volume>
          <issue>5</issue>
          <fpage>581</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="doi">10.1007/s10875-008-9196-1</pub-id>
          <pub-id pub-id-type="pmid">18481161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heltzer</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Ernst</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>A potential screening tool for IPEX syndrome</article-title>
          <source>Pediatr Dev Pathol</source>
          <year>2007</year>
          <volume>10</volume>
          <issue>2</issue>
          <fpage>98</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="doi">10.2350/06-07-0130.1</pub-id>
          <pub-id pub-id-type="pmid">17378693</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torgerson</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Linane</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Anover</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mateo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hermine</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Vijay</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gambineri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cerf-Bensussan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene</article-title>
          <source>Gastroenterology</source>
          <year>2007</year>
          <volume>132</volume>
          <fpage>1705</fpage>
          <lpage>1717</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2007.02.044</pub-id>
          <pub-id pub-id-type="pmid">17484868</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moes</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Begue</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Verdier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Patey</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stolzenberg</surname>
              <given-names>M-C</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rings</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>J-L</given-names>
            </name>
            <name>
              <surname>Piloquet</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Biver</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Breton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Hermine</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Cerf-Bensussan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy</article-title>
          <source>Gastroenterology</source>
          <year>2010</year>
          <volume>139</volume>
          <fpage>770</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.006</pub-id>
          <pub-id pub-id-type="pmid">20537998</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hennezel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bin</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Piccirillo</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome</article-title>
          <source>J Med Genet</source>
          <year>2012</year>
          <volume>49</volume>
          <fpage>291</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="doi">10.1136/jmedgenet-2012-100759</pub-id>
          <pub-id pub-id-type="pmid">22581967</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taddio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Faleschini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Valencic</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Granzotto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tommasini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lepore</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Andolina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barbi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritionaland immunosuppressive therapy</article-title>
          <source>Eur J Pediatr</source>
          <year>2007</year>
          <volume>166</volume>
          <issue>11</issue>
          <fpage>1195</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-006-0395-6</pub-id>
          <pub-id pub-id-type="pmid">17205241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>d&#x2019;Hennezel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ben-Shoshan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Lejtenyi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Noya</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Jabado</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mazer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Piccirillo</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>361</volume>
          <fpage>1710</fpage>
          <lpage>1713</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc0907093</pub-id>
          <pub-id pub-id-type="pmid">19846862</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorsey</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Petrovic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Dishaw</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Sleasman</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning</article-title>
          <source>Immunol Res</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>179</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.1007/s12026-009-8112-y</pub-id>
          <pub-id pub-id-type="pmid">19471859</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubio-Cabezas</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Minton</surname>
              <given-names>JAL</given-names>
            </name>
            <name>
              <surname>Caswell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shield</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Deiss</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sumnik</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Cayssials</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Herr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Loew</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ellard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hattersley</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes</article-title>
          <source>Diabetes Care</source>
          <year>2009</year>
          <volume>32</volume>
          <fpage>111</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="doi">10.2337/dc08-1188</pub-id>
          <pub-id pub-id-type="pmid">18931102</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lucas</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Ungar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Comito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Groh</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Epstein Barr virus induced lymphoma in a child with IPEX syndrome</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2008</year>
          <volume>50</volume>
          <fpage>1056</fpage>
          <lpage>1057</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.21341</pub-id>
          <pub-id pub-id-type="pmid">17828748</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patey-Mariaud de Serre</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Canioni</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ganousse</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Goulet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ruemmele</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brousse</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Digestive histopathological presentation of IPEX syndrome</article-title>
          <source>Mod Pathol</source>
          <year>2009</year>
          <volume>22</volume>
          <fpage>95</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.2008.161</pub-id>
          <pub-id pub-id-type="pmid">18820676</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McMurchy</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Gillies</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Allan</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Passerini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gambineri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Roncarolo</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Bacchetta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Levings</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2010</year>
          <volume>126</volume>
          <fpage>1242</fpage>
          <lpage>1251</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2010.09.001</pub-id>
          <pub-id pub-id-type="pmid">21036387</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
